STLN Starling Oncology, Inc.
6.430USD-2.28%Mkt Cap: 655.32M $P/E: —1d ago
Starling Oncology, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company of…
Industry Peers
Medical Care Facilities$97.43BUSDP/E 14.7
$26.50BUSDP/E 15.6
$20.92BUSDP/E 10.1
$12.08BUSDP/E 20.5
$11.35BUSDP/E 14.9
$10.92BUSDP/E 11.3
$11.01BUSDP/E 10.7
$10.29BUSDP/E 7.1
$9.86BUSDP/E 26.5
$6.84BUSDP/E 25.3
$6.55BUSDP/E 25.2
$4.65BUSDP/E 23.5
$4.64BUSDP/E 23.5
$4.60BUSDP/E 93.2
$3.78BUSDP/E 42.6
$3.46BUSDP/E 24.9
$2.72BUSD
$2.69BUSDP/E 9.8
$2.58BUSDP/E 39.5
$2.57BUSD
| Headline | Source | Time |
|---|---|---|
Older | ||
 Oncology Institute Q2 Earnings Call Highlights Oncology Institute (NASDAQ:TOI) reported second-quarter revenue growth, positive adjusted EBITDA and an expanded pipeline of value-based oncology contracts as the company announced it has rebranded as Starling Oncology. Chief Executive Officer Dan Virnich said the new name reflects the company’s ev | ||
 The Oncology Institute, Inc. (STLN) Reports Q2 Loss, Tops Revenue Estimates STARLING ONCOLO (STLN) delivered earnings and revenue surprises of -14.29% and +5.55%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||